PUBLISHED FOR OPPOSITION
on 26 Nov 2024
Last Applicant/ Owned by
F-33600 PESSAC
FR
Serial Number
79390168 filed on 07th Nov 2023
Registration Number
N/A
Correspondent Address
Rebeccah Gan
Filing Basis
1. filing basis filed as 66 a
Disclaimer
NO DATA
GIGALLOLINE
Laboratory research in the field of biotechnology; scientific research on stem cells; scientific research on the production of pluripotent stem cells by encapsulation; research and development in the field of stem cells, cell and gene therapy and biotechnology; pharmaceutical research and development; scientific laboratory services; providing information with respect to scientific research in the Read More
Classification Information
Class [042]
Computer & Software Services & Scientific Services
Laboratory research in the field of biotechnology; scientific research on stem cells; scientific research on the production of pluripotent stem cells by encapsulation; research and development in the field of stem cells, cell and gene therapy and biotechnology; pharmaceutical research and development; scientific laboratory services; providing information with respect to scientific research in the field of stem cells, cell and gene therapy and biotechnology
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
Pharmaceutical products for the treatment of Parkinson's disease and neurodegenerative diseases, heart failure, diabetes, Non-Alcoholic Steatohepatitis and acute liver failure, Age-related macular degeneration and limbal stem cells deficiencies, traumatic injury and skin burns, spinal cord injuries, Huntington disease, amyotrophic lateral sclerosis, Alzheimer's disease, stroke, burns, cancer, osteoarthritis, Multiple Sclerosis, Radiation Induced Intestinal Injury, Inflammatory Bowel Disease, Liver Disease, Duchenne Muscular Dystrophy, Bone Disease, Renal Disease, Chronic Wounds, Graft-Versus-Host Disease, Sepsis and Respiratory diseases, functional microtissues that facilitate transplantation and graft integration; pharmaceutical preparations for the treatment of Parkinson's disease and neurodegenerative diseases, heart failure, diabetes, Non-Alcoholic Steatohepatitis and acute liver failure, Age-related macular degeneration and limbal stem cells deficiencies, traumatic injury and skin burns, spinal cord injuries, Huntington disease, amyotrophic lateral sclerosis, Alzheimer's disease, stroke, burns, cancer, osteoarthritis, Multiple Sclerosis, Radiation Induced Intestinal Injury, Inflammatory Bowel Disease, Liver Disease, Duchenne Muscular Dystrophy, Bone Disease, Renal Disease, Chronic Wounds, Graft-Versus-Host Disease, Sepsis and Respiratory diseases, functional microtissues that facilitate transplantation and graft integration; stem cells for medical or veterinary use; pluripotent stem cells for medical use intended for cell and gene therapies; cultures of cell media for medical and veterinary use; surgical implants comprised of living tissues obtained from stem cells
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [001]
Chemical Products
Stem cells for research; stem cells for scientific purposes; nutrition agents, namely, cell culture reagents for scientific and research use for processing living cells other than for medical purposes; cell culture media other than for medical and veterinary purposes
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 79390168
Mark Type
No Service Mark
Attorney Docket Number
No TM23-0550
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
Yes
66A Current
Yes
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 26th Nov 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 26th Nov 2024 | PUBLISHED FOR OPPOSITION |
| 20th Nov 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 30th Oct 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 29th Oct 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| 28th Oct 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| 28th Oct 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| 21st Jul 2024 | REFUSAL PROCESSED BY IB |
| 28th Jun 2024 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| 28th Jun 2024 | REFUSAL PROCESSED BY MPU |